newsfilter
← Latest News
ACCESS Newswire·

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

  • Telomir Pharmaceuticals, Inc. successfully closed its stock-for-stock acquisition of TELI Pharmaceuticals, Inc. on April 24, 2026.
  • The transaction received shareholder approval at the Annual Meeting held on March 23, 2026.
  • Telomir now holds sole global ownership rights to its lead candidate, Telomir-1 (Telomir-Zn), eliminating prior geographic fragmentation of rights.
  • Telomir received an initial $1.0 million funding at closing.
  • The deal includes potential additional milestone-based contributions of up to $4.0 million from former TELI shareholders tied to IND acceptance and Phase 1/2 trial initiation.
  • Former TELI shareholders received Telomir common stock based on an independent exchange ratio, subject to a six-month lock-up.
  • Telomir recently submitted an Investigational New Drug (IND) application to the FDA for Telomir-Zn to treat advanced and metastatic triple-negative breast cancer.
  • Upon IND clearance, the Company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-Zn as an oral monotherapy for the specified cancer type.
  • Telomir is now positioned to advance clinical development while retaining flexibility to evaluate global partnership opportunities.